Relay racing down accelerated pathway with promising bile duct cancer readout
Latest data cut shows response rates to computationally designed selective FGFR2 inhibitor, built for efficacy with improved safety profile
Relay added more than $650 million in market cap Thursday after an ESMO presentation showed that the company’s selective FGFR inhibitor led to an 88.2% objective response rate at the recommended pivotal dose among patients with cholangiocarcinoma, suggesting the therapy’s path to accelerated approval could be a relatively short one.
An abstract released ahead of this weekend’s European Society for Medical Oncology meeting featured the latest data cut from the Phase I/II ReFocus study of RLY-4008. Among 17 patients receiving the study’s once-daily 70 mg dose of the molecule, 15 had responses, all of which were ongoing through an Aug. 1 cutoff. One patient with a near-complete response had a resection “with curative intent,” the abstract said...